1h Free Analyst Time
Speak directly to the analyst to clarify any post sales queries you may have.
About this market
The improved diagnostic modalities for haemorrhagic stroke recovery to help market grow. For the appropriate management of haemorrhagic stroke, an adequate understanding of parenchymal haemorrhage is crucial. Since intracerebral haemorrhage is an acute clinical manifestation of the underlying cerebral small vessel diseases (cSVDs), it is essential to use improved diagnostic modalities such as MRI markers to monitor the risk stratification. The analysts have predicted that the haemorrhagic stroke treatment market will register a CAGR of almost 4% by 2023.
Market Overview
Rising incidence in aging population
Increasing age is a major risk for several conditions, including intracerebral haemorrhages. This increases the demand for drugs thereby pushing growth in the haemorrhagic stroke treatment market.
High generic influx
The patent expiry of most of the products has paved the way for the entry of generics into the market. The excessive use of generic medicine can impede the demand for branded drugs, thereby affecting the market.
For the detailed list of factors that will drive and challenge the growth of the haemorrhagic stroke treatment market during the 2019-2023, view the full report.
Competitive Landscape
The market appears to be fragmented and with the presence of several companies including Baxter and Novartis, the competitive environment is quite intense. Factors such as the improved diagnostic modalities for haemorrhagic stroke recovery and the rising incidence in aging population, will provide considerable growth opportunities to haemorrhagic stroke treatment manufactures. Baxter, Novartis, Sanofi, and Pfizer are some of the major companies covered in this report.
With the presence of a considerable number of companies, this market appears to be fragmented. This market research report will help clients identify new growth opportunities and design unique growth strategies by providing a comprehensive analysis of the markets competitive landscape and offering information on the products offered by companies.
The improved diagnostic modalities for haemorrhagic stroke recovery to help market grow. For the appropriate management of haemorrhagic stroke, an adequate understanding of parenchymal haemorrhage is crucial. Since intracerebral haemorrhage is an acute clinical manifestation of the underlying cerebral small vessel diseases (cSVDs), it is essential to use improved diagnostic modalities such as MRI markers to monitor the risk stratification. The analysts have predicted that the haemorrhagic stroke treatment market will register a CAGR of almost 4% by 2023.
Market Overview
Rising incidence in aging population
Increasing age is a major risk for several conditions, including intracerebral haemorrhages. This increases the demand for drugs thereby pushing growth in the haemorrhagic stroke treatment market.
High generic influx
The patent expiry of most of the products has paved the way for the entry of generics into the market. The excessive use of generic medicine can impede the demand for branded drugs, thereby affecting the market.
For the detailed list of factors that will drive and challenge the growth of the haemorrhagic stroke treatment market during the 2019-2023, view the full report.
Competitive Landscape
The market appears to be fragmented and with the presence of several companies including Baxter and Novartis, the competitive environment is quite intense. Factors such as the improved diagnostic modalities for haemorrhagic stroke recovery and the rising incidence in aging population, will provide considerable growth opportunities to haemorrhagic stroke treatment manufactures. Baxter, Novartis, Sanofi, and Pfizer are some of the major companies covered in this report.
With the presence of a considerable number of companies, this market appears to be fragmented. This market research report will help clients identify new growth opportunities and design unique growth strategies by providing a comprehensive analysis of the markets competitive landscape and offering information on the products offered by companies.
Note: Product cover images may vary from those shown
PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
PART 03: MARKET LANDSCAPE
PART 05: MARKET SIZING
PART 09: MARKET SEGMENTATION BY TYPE
PART 10: GEOGRAPHIC LANDSCAPE
PART 12: DRIVERS AND CHALLENGES
PART 14: VENDOR LANDSCAPE
Exhibit 01: Global CNS therapeutics market
Exhibit 02: Segments of global CNS therapeutics market
Exhibit 03: Market characteristics
Exhibit 04: Market segments
Exhibit 05: Pipeline molecules for hemorrhagic stroke treatment
Exhibit 06: Market definition - Inclusions and exclusions checklist
Exhibit 07: Market size 2018
Exhibit 08: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 09: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 10: Five forces analysis 2018
Exhibit 11: Five forces analysis 2023
Exhibit 12: Bargaining power of buyers
Exhibit 13: Bargaining power of suppliers
Exhibit 14: Threat of new entrants
Exhibit 15: Threat of substitutes
Exhibit 16: Threat of rivalry
Exhibit 17: Market condition - Five forces 2018
Exhibit 18: Product - Market share 2018-2023 (%)
Exhibit 19: Comparison by product
Exhibit 20: Antihypertensives - Market size and forecast 2018-2023 ($ millions)
Exhibit 21: Antihypertensives - Year-over-year growth 2019-2023 (%)
Exhibit 22: Anticoagulants - Market size and forecast 2018-2023 ($ millions)
Exhibit 23: Anticoagulants - Year-over-year growth 2019-2023 (%)
Exhibit 24: Diuretics - Market size and forecast 2018-2023 ($ millions)
Exhibit 25: Diuretics - Year-over-year growth 2019-2023 (%)
Exhibit 26: Anticonvulsants and others - Market size and forecast 2018-2023 ($ millions)
Exhibit 27: Anticonvulsants and others - Year-over-year growth 2019-2023 (%)
Exhibit 28: Market opportunity by product
Exhibit 29: Customer landscape
Exhibit 30: Market share by geography 2018-2023 (%)
Exhibit 31: Geographic comparison
Exhibit 32: Americas - Market size and forecast 2018-2023 ($ millions)
Exhibit 33: Americas - Year-over-year growth 2019-2023 (%)
Exhibit 34: APAC - Market size and forecast 2018-2023 ($ millions)
Exhibit 35: APAC - Year-over-year growth 2019-2023 (%)
Exhibit 36: EMEA - Market size and forecast 2018-2023 ($ millions)
Exhibit 37: EMEA - Year-over-year growth 2019-2023 (%)
Exhibit 38: Key leading countries
Exhibit 39: Market opportunity
Exhibit 40: Impact of drivers and challenges
Exhibit 41: Interventions for improving drug delivery to BBB
Exhibit 42: Vendor landscape
Exhibit 43: Landscape disruption
Exhibit 44: Vendors covered
Exhibit 45: Vendor classification
Exhibit 46: Market positioning of vendors
Exhibit 47: Baxter - Vendor overview
Exhibit 48: Baxter - Business segments
Exhibit 49: Baxter - Organizational developments
Exhibit 50: Baxter - Geographic focus
Exhibit 51: Baxter - Key offerings
Exhibit 52: Novartis - Vendor overview
Exhibit 53: Novartis - Business segments
Exhibit 54: Novartis - Organizational developments
Exhibit 55: Novartis - Geographic focus
Exhibit 56: Novartis - Segment focus
Exhibit 57: Novartis - Key offerings
Exhibit 58: Pfizer - Vendor overview
Exhibit 59: Pfizer - Business segments
Exhibit 60: Pfizer - Organizational developments
Exhibit 61: Pfizer - Geographic focus
Exhibit 62: Pfizer - Segment focus
Exhibit 63: Pfizer - Key offerings
Exhibit 64: Sanofi - Vendor overview
Exhibit 65: Sanofi - Business segments
Exhibit 66: Sanofi - Organizational developments
Exhibit 67: Sanofi - Segment focus
Exhibit 68: Sanofi - Segment focus
Exhibit 69: Sanofi - Key offerings
PART 02: SCOPE OF THE REPORT
PART 03: MARKET LANDSCAPE
- Market ecosystem
- Market characteristics
- Market segmentation analysis
PART 05: MARKET SIZING
- Market definition
- Market sizing 2018
- Market size and forecast 2018-2023
- Bargaining power of buyers
- Bargaining power of suppliers
- Threat of new entrants
- Threat of substitutes
- Threat of rivalry
- Market condition
- Market segmentation by product
- Comparison by product
- Antihypertensives - Market size and forecast 2018-2023
- Anticoagulants - Market size and forecast 2018-2023
- Diuretics - Market size and forecast 2018-2023
- Anticonvulsants and others - Market size and forecast 2018-2023
- Market opportunity by product
PART 09: MARKET SEGMENTATION BY TYPE
PART 10: GEOGRAPHIC LANDSCAPE
- Geographic segmentation
- Geographic comparison
- Americas - Market size and forecast 2018-2023
- APAC - Market size and forecast 2018-2023
- EMEA - Market size and forecast 2018-2023
- Key leading countries
- Market opportunity
PART 12: DRIVERS AND CHALLENGES
- Market drivers
- Market challenges
PART 14: VENDOR LANDSCAPE
- Overview
- Landscape disruption
- Vendors covered
- Vendor classification
- Market positioning of vendors
- Baxter
- Novartis
- Pfizer
- Sanofi
- Research methodology
- List of abbreviations
Exhibit 01: Global CNS therapeutics market
Exhibit 02: Segments of global CNS therapeutics market
Exhibit 03: Market characteristics
Exhibit 04: Market segments
Exhibit 05: Pipeline molecules for hemorrhagic stroke treatment
Exhibit 06: Market definition - Inclusions and exclusions checklist
Exhibit 07: Market size 2018
Exhibit 08: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 09: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 10: Five forces analysis 2018
Exhibit 11: Five forces analysis 2023
Exhibit 12: Bargaining power of buyers
Exhibit 13: Bargaining power of suppliers
Exhibit 14: Threat of new entrants
Exhibit 15: Threat of substitutes
Exhibit 16: Threat of rivalry
Exhibit 17: Market condition - Five forces 2018
Exhibit 18: Product - Market share 2018-2023 (%)
Exhibit 19: Comparison by product
Exhibit 20: Antihypertensives - Market size and forecast 2018-2023 ($ millions)
Exhibit 21: Antihypertensives - Year-over-year growth 2019-2023 (%)
Exhibit 22: Anticoagulants - Market size and forecast 2018-2023 ($ millions)
Exhibit 23: Anticoagulants - Year-over-year growth 2019-2023 (%)
Exhibit 24: Diuretics - Market size and forecast 2018-2023 ($ millions)
Exhibit 25: Diuretics - Year-over-year growth 2019-2023 (%)
Exhibit 26: Anticonvulsants and others - Market size and forecast 2018-2023 ($ millions)
Exhibit 27: Anticonvulsants and others - Year-over-year growth 2019-2023 (%)
Exhibit 28: Market opportunity by product
Exhibit 29: Customer landscape
Exhibit 30: Market share by geography 2018-2023 (%)
Exhibit 31: Geographic comparison
Exhibit 32: Americas - Market size and forecast 2018-2023 ($ millions)
Exhibit 33: Americas - Year-over-year growth 2019-2023 (%)
Exhibit 34: APAC - Market size and forecast 2018-2023 ($ millions)
Exhibit 35: APAC - Year-over-year growth 2019-2023 (%)
Exhibit 36: EMEA - Market size and forecast 2018-2023 ($ millions)
Exhibit 37: EMEA - Year-over-year growth 2019-2023 (%)
Exhibit 38: Key leading countries
Exhibit 39: Market opportunity
Exhibit 40: Impact of drivers and challenges
Exhibit 41: Interventions for improving drug delivery to BBB
Exhibit 42: Vendor landscape
Exhibit 43: Landscape disruption
Exhibit 44: Vendors covered
Exhibit 45: Vendor classification
Exhibit 46: Market positioning of vendors
Exhibit 47: Baxter - Vendor overview
Exhibit 48: Baxter - Business segments
Exhibit 49: Baxter - Organizational developments
Exhibit 50: Baxter - Geographic focus
Exhibit 51: Baxter - Key offerings
Exhibit 52: Novartis - Vendor overview
Exhibit 53: Novartis - Business segments
Exhibit 54: Novartis - Organizational developments
Exhibit 55: Novartis - Geographic focus
Exhibit 56: Novartis - Segment focus
Exhibit 57: Novartis - Key offerings
Exhibit 58: Pfizer - Vendor overview
Exhibit 59: Pfizer - Business segments
Exhibit 60: Pfizer - Organizational developments
Exhibit 61: Pfizer - Geographic focus
Exhibit 62: Pfizer - Segment focus
Exhibit 63: Pfizer - Key offerings
Exhibit 64: Sanofi - Vendor overview
Exhibit 65: Sanofi - Business segments
Exhibit 66: Sanofi - Organizational developments
Exhibit 67: Sanofi - Segment focus
Exhibit 68: Sanofi - Segment focus
Exhibit 69: Sanofi - Key offerings
Note: Product cover images may vary from those shown
Global Haemorrhagic Stroke Treatment Market 2019-2023
The author of the report recognizes the following companies as the key players in the global haemorrhagic stroke treatment market: Baxter, Novartis, Sanofi, and Pfizer.
Commenting on the report, an analyst from the research team said: “The latest trend gaining momentum in the market is the improved diagnostic modalities for haemorrhagic stroke recovery.”
According to the report, one of the major drivers for this market is the rising incidence in aging population.
Further, the report states that one of the major factors hindering the growth of this market is the high generic influx.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
The author of the report recognizes the following companies as the key players in the global haemorrhagic stroke treatment market: Baxter, Novartis, Sanofi, and Pfizer.
Commenting on the report, an analyst from the research team said: “The latest trend gaining momentum in the market is the improved diagnostic modalities for haemorrhagic stroke recovery.”
According to the report, one of the major drivers for this market is the rising incidence in aging population.
Further, the report states that one of the major factors hindering the growth of this market is the high generic influx.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Note: Product cover images may vary from those shown
- Baxter
- Novartis
- Pfizer
- Sanofi
Note: Product cover images may vary from those shown
LOADING...
